Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
World J Gastroenterol ; 29(26): 4174-4185, 2023 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-37475845

RESUMEN

Neuroendocrine neoplasms (NENs) are rare heterogeneous tumors that can develop in almost any organ, with the digestive organs, including the gastrointestinal tract and pancreas being the most commonly affected sites. Despite the fact that advances in initial therapies have progressed, there is presently no recognized effective treatment for advanced NEN. Immune checkpoint inhibitors (ICIs) have shown superior efficacy in treating several types of solid tumors. Despite their successful role in the treatment of partial NENs, such as small cell lung cancer, and Merkel cell carcinoma, the role of ICIs in most of the NENs remains limited. Nevertheless, due to their specific anti-tumor mechanisms and acceptable safety profile, ICIs are a promising avenue for further study in NENs therapy. Recent clinical trials have illustrated that combination therapy with ICI is more efficient than monotherapy, and multiple clinical trials are constantly ongoing to evaluate the efficacy and safety of these combination therapies. Therefore, the purpose of this review is to provide a comprehensive summary of the clinical progress of immunotherapy in NENs affecting the digestive system, with a specific emphasis on the application of programmed cell death protein 1/programmed death receptor ligand 1 inhibitor. Furthermore, this review has an exploration of the potential beneficiary population and the inherent value of utilizing immunotherapy in the management of NENs.


Asunto(s)
Tumores Neuroendocrinos , Humanos , Tumores Neuroendocrinos/tratamiento farmacológico , Resultado del Tratamiento , Inmunoterapia/efectos adversos , Terapia Combinada , Páncreas/patología
2.
World J Gastroenterol ; 23(10): 1920-1924, 2017 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-28348499

RESUMEN

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal tumors of the alimentary tract. These tumors may have different clinical and biological behaviors. Malignant forms usually spread via a hematogenous route, and lymph node metastases rarely occur. Herein, we report a patient with a jejunal GIST who developed supraclavicular lymph node metastasis. We conclude that lymphatic diffusion via the mediastinal lymphatic station to the supraclavicular lymph nodes can be a potential metastatic route for GISTs.


Asunto(s)
Tumores del Estroma Gastrointestinal/complicaciones , Tumores del Estroma Gastrointestinal/patología , Melena/etiología , Neoplasias Gástricas/complicaciones , Neoplasias Gástricas/patología , Antineoplásicos/administración & dosificación , Antineoplásicos/uso terapéutico , Biopsia con Aguja , Quimioterapia Adyuvante , Transfusión de Eritrocitos , Tumores del Estroma Gastrointestinal/diagnóstico , Tumores del Estroma Gastrointestinal/terapia , Humanos , Mesilato de Imatinib/administración & dosificación , Mesilato de Imatinib/uso terapéutico , Yeyuno/patología , Yeyuno/cirugía , Ganglios Linfáticos/patología , Metástasis Linfática , Masculino , Melena/terapia , Persona de Mediana Edad , Disección del Cuello , Clasificación del Tumor , Tomografía Computarizada por Tomografía de Emisión de Positrones , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/terapia , Ultrasonografía
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda